8:50-9:15

Abstract 8002

First-line crizotinib versus   pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with   advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC):   results of a phase III study (PROFILE 1014).

一线克唑替尼对比培美曲塞/顺铂或培美曲塞/卡铂治疗ALK阳性晚期非鳞癌非小细胞肺癌：III期临床研究结果(PROFILE 1014)。

周  清(Qing Zhou)

Abstract   8003^

Ceritinib   in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell   lung cancer (NSCLC): Results of the ASCEND-1 trial.

Ceritinib治疗ALK阳性晚期非小细胞肺癌：ASCEND-1研究结果。

Abstract 8009^

Clinical activity of the mutant selective   EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor resistant   non-small cell lung cancer (NSCLC).

选择性EGFR抑制剂AZD9291治疗EGFR抑制剂耐药的非小细胞肺癌的疗效。

9:15-9:30

专家评述

Discussion Topic: Current approach to ALK+ive lung cancer

讨论主题：ALK阳性肺癌的治疗策略

Lam   Kwok Chi

翻译：

徐崇锐(Chong-Rui Xu)

9:30-9:35

讨论(Q &   A)

吴一龙(Yi-Long Wu)

程  颖(Ying Cheng)

Lam Kwok Chi